Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 21st International Congress of the Society for Melanoma Research (SMR), which was held in New Orleans, LA, on 10-13 October 2024, brought together experts in melanoma to exchange the most recent breakthroughs in cancer science and medicine.

SMR 2024

10–13 October 2024 | New Orleans, LA

SMR 2024

10–13 October 2024 | New Orleans, LA
The 21st International Congress of the Society for Melanoma Research (SMR), which was held in New Orleans, LA, on 10-13 October 2024, brought together experts in melanoma to exchange the most recent breakthroughs in cancer science and medicine.
Enhancing ctDNA monitoring for prime time use in high-risk melanoma 2:47
Enhancing ctDNA monitoring for prime time use in high-risk melanoma
Meghan Mooradian • 1 Nov 2024
The growing role of cellular therapy in NRAS-mutant melanoma 1:20
The growing role of cellular therapy in NRAS-mutant melanoma
Janice Mehnert • 28 Oct 2024
How can ctDNA assays improve clinical decisions in high-risk melanoma? 1:53
How can ctDNA assays improve clinical decisions in high-risk melanoma?
Meghan Mooradian • 1 Nov 2024
The potential of rechallenging the RAF pathway with NRAS inhibitors in melanoma 1:03
The potential of rechallenging the RAF pathway with NRAS inhibitors in melanoma
Janice Mehnert • 28 Oct 2024
IGNYTE: RP1 with nivolumab in anti-PD1-resistant melanoma 3:43
IGNYTE: RP1 with nivolumab in anti-PD1-resistant melanoma
Gino In • 22 Oct 2024
Advances in oncolytic immunotherapy for melanoma: vusolimogene oderparepvec 3:54
Advances in oncolytic immunotherapy for melanoma: vusolimogene oderparepvec
Gino In • 22 Oct 2024
Outlook on the future of oncolytic immunotherapy for skin cancer 1:20
Outlook on the future of oncolytic immunotherapy for skin cancer
Gino In • 22 Oct 2024
Enhanced monitoring of high-risk resectable melanoma with plasma ctDNA assays 3:15
Enhanced monitoring of high-risk resectable melanoma with plasma ctDNA assays
Meghan Mooradian • 1 Nov 2024
Exploring the role of personalized ctDNA monitoring in high-risk melanoma 3:12
Exploring the role of personalized ctDNA monitoring in high-risk melanoma
Meghan Mooradian • 1 Nov 2024
Exploring the role of lifileucel in the treatment of melanoma brain metastases 3:37
Exploring the role of lifileucel in the treatment of melanoma brain metastases
Allison Betof Warner • 15 Oct 2024
Current treatment options for brain metastases in advanced melanoma 1:25
Current treatment options for brain metastases in advanced melanoma
Allison Betof Warner • 15 Oct 2024
Results from a pilot trial evaluating lifileucel in melanoma brain metastases 1:57
Results from a pilot trial evaluating lifileucel in melanoma brain metastases
Allison Betof Warner • 15 Oct 2024
Results from a Phase I trial evaluating exarafenib in NRAS-mutant melanoma 1:18
Results from a Phase I trial evaluating exarafenib in NRAS-mutant melanoma
Janice Mehnert • 28 Oct 2024
Importance of pan-RAF inhibitors in the future of melanoma treatment 0:46
Importance of pan-RAF inhibitors in the future of melanoma treatment
Janice Mehnert • 28 Oct 2024
Evaluating the role of gut and tumor microbiome in melanoma immunotherapy 1:17
Evaluating the role of gut and tumor microbiome in melanoma immunotherapy
Saman Maleki • 22 Oct 2024
Fecal microbial transplantation combined with anti-PD-1 therapy in melanoma 0:40
Fecal microbial transplantation combined with anti-PD-1 therapy in melanoma
Saman Maleki • 22 Oct 2024
The content of VJOncology is intended for healthcare professionals